Lisata Therapeutics (LSTA) Projected to Post Quarterly Earnings on Thursday

Lisata Therapeutics (NASDAQ:LSTA) is anticipated to post its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect Lisata Therapeutics to post earnings of ($0.76) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Lisata Therapeutics Stock Performance

LSTA stock opened at $2.41 on Wednesday. Lisata Therapeutics has a 52 week low of $2.19 and a 52 week high of $4.20. The firm’s fifty day moving average is $2.97 and its 200 day moving average is $2.92. The firm has a market cap of $20.19 million, a P/E ratio of -0.96 and a beta of 1.14.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Lisata Therapeutics in a report on Wednesday, December 11th.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.